FOI 2024-024

Data below is from the period 01 January 2024 to 31 March 2024

Q1. How many patients have been treated (for any condition) in the last 4 months with:

·       Benralizumab - NIL

·       Dupilumab - 147

·       Omalizumab - 24

·       Reslizumab - NIL

·       Mepolizumab - NIL

·       Tezepelumab - NIL

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups: 

·       Age 6-11 - NIL

·       Age 12-17 - NIL

·       Age 18 and above - 171

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

·       Dupilumab -

·       Omalizumab -

Unfortunately, the information requested is unable to be provided.  The Trust does not have this information readily available and to obtain all of the required information would require a manual search which would take in excess of 18 hours as specified under Section 12 of the Freedom of Information Act.